Quick Order Cart

Cat. No. ARG43975

Mettl3 Knockout Neuro-2a Cell Line

  • Product Type:

    In Stock Cell Lines

  • Species:

    Mus musculus (Mouse)

  • Tissue Source:

    Brain

  • Disease:

    Neuroblastoma

This CRISPR/Cas9-edited Mettl3 knockout Neuro-2a cell line provides a robust loss-of-function model for studying m6A RNA methylation in neuronal differentiation. Mettl3, the catalytic subunit of the m6A writer complex, is disrupted in the widely used mouse neuroblastoma Neuro-2a background, which is well suited for neurite outgrowth and neurodevelopment assays. By eliminating Mettl3-dependent methylation of key transcripts such as Neurog2 and Mapt, the line enables investigation of epitranscriptomic control of mRNA stability and translation. Applications include m6A MeRIP-seq, transcriptomic profiling, and functional neuronal assays, making it ideal for neurobiology and disease modeling research.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    Neuro-2a

    Sex of Donor

    Male

    Age

    Unknown

    Gene Name

    Mettl3

    Gene Identifier

    NCBI Gene ID 56335

    Morphology

    Neuronal and amoeboid stem cells

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

This product is a CRISPR/Cas9-edited Mettl3 knockout cell line derived from Neuro-2a cells. Through CRISPR/Cas9-mediated gene disruption, the Mettl3 locus has been targeted to eliminate expression of the catalytic subunit of the N6-methyladenosine (m6A) methyltransferase complex, providing a clean loss-of-function model for epitranscriptomic research.

Neuro-2a is a mouse neural crest-derived neuroblastoma line, a subclone of C1300, extensively utilized as a neuronal model for studying differentiation and neurite outgrowth. Serum starvation induces these cells to extend neurites and express neuronal markers, making them ideal for investigating molecular mechanisms of neurogenesis.

Mettl3 associates with METTL14, WTAP, VIRMA, RBM15, and ZC3H13 to form the m6A writer complex, which catalyzes co-transcriptional deposition of m6A on mRNA. This modification influences RNA stability, splicing, and translation. Mettl3 activity is modulated by upstream regulators including WTAP, c-Myc, and KMT2A, and its catalytic output directly methylates transcripts such as Neurog2, Mapt, Bdnf, and Sox2 mRNAs. Recognition of m6A marks by reader proteins (YTHDF1, YTHDF2, YTHDF3) and removal by erasers (FTO, ALKBH5) complete a dynamic regulatory network.

In the Neuro-2a neuronal context, Mettl3-mediated m6A methylation is critical for the post-transcriptional control of genes driving neuronal differentiation. Knockout of Mettl3 destabilizes key mRNAs, including Neurog2 and Mapt, resulting in impaired neurite outgrowth and neuronal maturation. This cell line thus enables dissection of epitranscriptomic layers in neurodevelopment and serves as a model for m6A-related disorders such as neurodevelopmental syndromes and glioblastoma.

Researchers can apply this knockout line in m6A MeRIP-seq to map transcriptome-wide methylation changes, RNA-seq for differential expression analysis, and RT-qPCR for target gene validation. Functional assays include neurite outgrowth measurement, immunofluorescence staining for neuronal markers, and metabolic profiling. Additionally, the line is valuable for mechanistic studies of mRNA decay and translation, rescue experiments with wild-type or mutant Mettl3, and high-throughput screening of molecules targeting the m6A pathway. For further assistance, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)